<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-655" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Atenolol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rehman</surname>
            <given-names>Baryiah</given-names>
          </name>
          <aff>Keele University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sanchez</surname>
            <given-names>Daniela P.</given-names>
          </name>
          <aff>Boston University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Saumya</given-names>
          </name>
          <aff>University of Alberta, Mazankowski Alberta Heart Institute</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Baryiah Rehman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniela Sanchez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saumya Shah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-655.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Atenolol is a second-generation &#x003b2;-1&#x02013;selective adrenergic antagonist that helps lower the heart rate and blood pressure of&#x000a0;patients while also decreasing myocardial contractility. Atenolol is approved by the U.S. Food and Drug Administration (FDA) for treating&#x000a0;hypertension, angina pectoris, and acute myocardial infarction.&#x000a0;Off-label uses of atenolol&#x000a0;include the treatment of arrhythmias, migraine prophylaxis, paroxysmal supraventricular tachycardia, alcohol withdrawal, thyrotoxicosis, and prophylaxis against secondary myocardial infarction.&#x000a0;Atenolol&#x000a0;is an alternative to propranolol in the management of infantile hemangiomas. The mechanistic actions of atenolol&#x000a0;are complemented by several cardiovascular drugs when managing cardiac emergencies.</p>
        <p>This activity&#x000a0;provides a comprehensive overview of atenolol, covering its indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, and toxicity. This activity also&#x000a0;highlights the role of&#x000a0;an interprofessional team&#x000a0;in treating medical conditions using atenolol. Patient outcomes are optimized when this medication is utilized by a team of primary care, emergency medicine, and&#x000a0;consulting&#x000a0;specialists.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the FDA-approved indications and off-label uses for atenolol, including hypertension, angina, and acute myocardial infarction.</p></list-item><list-item><p>Screen patients for asthma, bronchospasm, or obstructive airway diseases to assess the&#x000a0;use of atenolol or consider alternative therapies.</p></list-item><list-item><p>Assess patients for adverse drug reactions and recognize potential complications, such as masked symptoms of hypoglycemia and thyrotoxicosis.</p></list-item><list-item><p>Collaborate within the interprofessional healthcare team to coordinate comprehensive care for patients using atenolol, ensuring regular renal function, heart rate, and blood pressure monitoring.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=655&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=655">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-655.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Atenolol is a second-generation &#x003b2;-1&#x02013;selective adrenergic antagonist that&#x000a0;helps&#x000a0;lower the heart rate and blood pressure of&#x000a0;patients while also decreasing myocardial contractility.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Atenolol is approved by the U.S. Food and Drug Administration (FDA) for treating&#x000a0;hypertension, angina pectoris, and acute myocardial infarction.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Off-label uses of atenolol&#x000a0;include the treatment of arrhythmias, migraine prophylaxis, paroxysmal supraventricular tachycardia, alcohol withdrawal, thyrotoxicosis, and prophylaxis against secondary myocardial infarction.<xref ref-type="bibr" rid="article-655.r1">[1]</xref><xref ref-type="bibr" rid="article-655.r2">[2]</xref>&#x000a0;Atenolol&#x000a0;is an alternative to propranolol in the management of infantile hemangiomas.<xref ref-type="bibr" rid="article-655.r3">[3]</xref>&#x000a0;The American Academy of Neurology (AAN) recommends atenolol as a treatment for episodic migraine.<xref ref-type="bibr" rid="article-655.r4">[4]</xref>&#x000a0;As per the guidelines from the American Society of Clinical Oncology, immune checkpoint inhibitors have the potential to induce thyrotoxicosis. The recommended management approach includes symptomatic control with atenolol/propranolol, along with recommended treatments such as steroids, saturated solution of potassium iodide, and methimazole.<xref ref-type="bibr" rid="article-655.r5">[5]</xref></p>
      </sec>
      <sec id="article-655.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Atenolol, a cardioselective &#x003b2;-1 adrenergic antagonist, selectively binds to the &#x003b2;-1 adrenergic receptors in vascular smooth muscle and the heart. This selective binding blocks the positive inotropic and chronotropic actions initiated by endogenous catecholamines such as isoproterenol, norepinephrine, and epinephrine. As a result, sympathetic stimulation is inhibited.<xref ref-type="bibr" rid="article-655.r6">[6]</xref>&#x000a0;This activity results in a decrease in heart rate, blood pressure, and myocardial contractility. However, atenolol can increase end-diastolic pressure and left ventricular fiber lengths in patients with heart failure, resulting in increased oxygen demand.</p>
        <p>In addition, atenolol exerts effects in higher doses by competitively blocking &#x003b2;-2 adrenoreceptors in the bronchial and vascular musculature. The drug lacks membrane-stabilizing or intrinsic sympathomimetic activity. Due to&#x000a0;the low lipid solubility, atenolol demonstrates reduced brain penetrance, which results in fewer adverse effects on the central nervous system.<xref ref-type="bibr" rid="article-655.r7">[7]</xref>&#x000a0;As beta-adrenergic receptor antagonists also increase the refractory period of the atrioventricular (AV node), they&#x000a0;may also be used off-label to&#x000a0;treat supraventricular tachycardia and prevent paroxysmal attacks of atrial fibrillation.<xref ref-type="bibr" rid="article-655.r8">[8]</xref> The duration of action for atenolol is dose-dependent. After administering a dose, the effects&#x000a0;are evident within&#x000a0;1 hour and peak at 2 to 4 hours, persisting for a minimum of 24 hours.<xref ref-type="bibr" rid="article-655.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The bioavailability of orally administered atenolol is approximately 50%.&#x000a0;Peak blood levels are&#x000a0;attained between 2 and 4 hours after oral administration and within 5 minutes after intravenous (IV) administration.</p>
        <p><bold>Distribution:</bold>&#x000a0;As previously mentioned, atenolol, a hydrophilic &#x003b2;-blocker with low lipid solubility, exhibits limited diffusion across the intestinal membrane and blood-brain barrier. The plasma protein binding of the drug is approximately 10%.<xref ref-type="bibr" rid="article-655.r10">[10]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;Atenolol undergoes minimal hepatic metabolism, with the parent drug being the predominant radiolabeled component in the blood.<xref ref-type="bibr" rid="article-655.r11">[11]</xref></p>
        <p><bold>Elimination:</bold> Atenolol is primarily excreted through the renal route, involving glomerular filtration and active secretion. The elimination half-life is approximately 6 to 7 hours.<xref ref-type="bibr" rid="article-655.r12">[12]</xref>&#x000a0;Organic cation transporters play an essential role in the elimination of atenolol.<xref ref-type="bibr" rid="article-655.r13">[13]</xref></p>
      </sec>
      <sec id="article-655.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Atenolol is available as oral tablets with strengths of 25, 50, and 100 mg and an&#x000a0;IV injection with a concentration of 0.5 mg/mL. The dosage and route of administration of the drug vary depending on the indication. Atenolol is also available in a fixed-drug combination with chlorthalidone for treating hypertension.</p>
        <p>
<bold>
<bold>Adult Dosage</bold>
</bold>
</p>
        <p><bold>Hypertension:</bold> The&#x000a0;recommended initial adult dosage of atenolol is 50 mg daily, administered as a single tablet or combined with diuretic therapy. If an adequate therapeutic response is not achieved after a few weeks, the dosage may be increased to a 100 mg tablet daily. Notably, daily doses exceeding this amount are unlikely to yield additional benefits.<xref ref-type="bibr" rid="article-655.r14">[14]</xref>&#x000a0;For older patients or those with renal impairment, a reduced daily dosage of 25 mg may be administered if their creatinine clearance is below 15 mL/min. In addition, monitoring&#x000a0;blood pressure is essential before administering a new dose.<xref ref-type="bibr" rid="article-655.r15">[15]</xref></p>
        <p><bold>Angina pectoris:&#x000a0;</bold>The recommended initial adult dosage of atenolol is 50 mg daily for non-vasospastic angina cases. If, after a week, the patient does not achieve the desired response, the dosage may be increased to&#x000a0;a 100 mg tablet daily. In certain cases, an optimal therapeutic response may necessitate a dosage of 200 mg daily. However, the withdrawal process should be gradual, and the patient should be closely monitored while advised to limit physical activity during this time.<xref ref-type="bibr" rid="article-655.r16">[16]</xref></p>
        <p><bold>Acute myocardial infarction:</bold>&#x000a0;IV injection should be administered promptly upon the patient's arrival at the hospital, ideally within 12 hours of the myocardial infarction. According to FDA recommendations, an adult should receive an initial&#x000a0;IV dose of 5 mg atenolol over 5 minutes and another 5 mg&#x000a0;IV injection after 10 minutes. A 50-mg oral dose should be administered to patients 12 hours later. Subsequently, oral dosing can consist of either 50 mg twice or 100 mg&#x000a0;daily for 6 to 9 days or until the patient is discharged from the hospital.<xref ref-type="bibr" rid="article-655.r17">[17]</xref></p>
        <p><bold>Migraine prophylaxis:</bold> The recommended initial adult daily dosage of atenolol is 25 mg daily, with titration every 1 to 2 weeks up to a maximum of 100 mg daily.<xref ref-type="bibr" rid="article-655.r18">[18]</xref></p>
        <p><bold>Supraventricular tachycardia:&#x000a0;</bold>According to the American College of Cardiology (ACC) and the American Heart Association (AHA) guidelines, the initial adult dosage of atenolol is 25 to 50 mg daily, with titration based on tolerability and response, up to a maximum of 100 mg daily.</p>
        <p><bold>Myocardial infarction:</bold> &#x003b2;-blocker initiation is recommended for most patients within 24 hours of a myocardial infarction. As part of secondary prophylaxis, the dosage should be gradually titrated up to 50 mg twice daily, considering blood pressure, heart rate, and potential adverse events.<xref ref-type="bibr" rid="article-655.r17">[17]</xref>&#x000a0;</p>
        <p><bold>Thyrotoxicosis:</bold> The recommended initial daily dosage of atenolol&#x000a0;is 25 to 50 mg daily, with titration as necessary to control symptoms such as tachycardia, palpitations, and tremulousness, up to a maximum of 100 mg twice-daily regimen.<xref ref-type="bibr" rid="article-655.r19">[19]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>The manufacturer's labeling does not specify dosage adjustments for atenolol in patients with hepatic impairment. Notably, as previously discussed, atenolol undergoes minimal hepatic metabolism.<xref ref-type="bibr" rid="article-655.r11">[11]</xref></p>
        <p><bold>Renal impairment:</bold> Patients with impaired renal function should undergo monitoring, and the dosage should be adjusted based on creatinine clearance.</p>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine clearance &#x0003e;30 mL/min: No dosage adjustment is needed.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine clearance between 10 and 30&#x000a0;mL/min: Maximum dosage should be up to 50 mg daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine clearance &#x0003c;10 mL/min: Maximum dosage should be up to 25 mg daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients undergoing hemodialysis:<bold>&#x000a0;</bold>As the procedure considerably clears atenolol, administering the drug after the dialysis session is recommended.<xref ref-type="bibr" rid="article-655.r15">[15]</xref><xref ref-type="bibr" rid="article-655.r20">[20]</xref></p>
          </list-item>
        </list>
        <p><bold>Pregnancy considerations:</bold> Atenolol was previously classified as an FDA pregnancy category D drug.<xref ref-type="bibr" rid="article-655.r21">[21]</xref>&#x000a0;According to the American College of Obstetricians and Gynecologists (ACOG) guidelines, atenolol is not recommended during pregnancy&#x000a0;due to the potential risk of growth restriction and low birth weight. The preferred &#x003b2;-blocker for chronic hypertension in pregnant women is labetalol.<xref ref-type="bibr" rid="article-655.r22">[22]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>The excretion of &#x003b2;-blockers in breast milk is primarily influenced by plasma protein binding. With its low plasma protein binding of 10%, atenolol is extensively excreted into breast milk. The accumulation of drugs in the infant is also associated with the fraction of the drug excreted in the urine. As atenolol has a substantial 85% renal excretion, a heightened risk of accumulation exists in infants, particularly neonates. Caution is advised in breastfeeding women. Alternative &#x003b2;-blockers may be preferred when nursing newborns and preterm infants.<xref ref-type="bibr" rid="article-655.r23">[23]</xref></p>
        <p><bold>Pediatric patients:</bold> Atenolol&#x000a0;does not have FDA approval for use in the pediatric population. However, clinicians may contemplate its off-label use in Marfan syndrome, infantile hemangioma, pediatric hypertension, and thyrotoxicosis.<xref ref-type="bibr" rid="article-655.r24">[24]</xref><xref ref-type="bibr" rid="article-655.r25">[25]</xref><xref ref-type="bibr" rid="article-655.r26">[26]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;According to ACC/AHA guidelines, in older patients, the accumulation of renally cleared drugs such as angiotensin-converting enzyme inhibitors (ACEi), atenolol, sotalol, and nadolol is influenced by reduced glomerular filtration, renal tubular function, and renal blood flow. Initiating atenolol is advised at a lower dose in this population.<xref ref-type="bibr" rid="article-655.r27">[27]</xref></p>
      </sec>
      <sec id="article-655.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>According to product labeling, the adverse effects of atenolol are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Common adverse effects include bradycardia, diarrhea, dizziness, constipation, confusion, dyspnea, headache, heart failure, erectile dysfunction, nausea, fatigue, paraesthesia, peripheral coldness, rash, sleep disorders, syncope, visual impairment, and bronchospasm.<xref ref-type="bibr" rid="article-655.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rare adverse effects include alopecia, dry mouth,&#x000a0;postural hypotension, psychosis, psoriasis, thrombocytopenia,&#x000a0;depression, mild transaminitis, and depression.<xref ref-type="bibr" rid="article-655.r29">[29]</xref><xref ref-type="bibr" rid="article-655.r30">[30]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The BRASH syndrome is characterized by severe bradycardia, renal failure, atrioventricular blockade, shock, and hyperkalemia. If suspicion of BRASH syndrome exists, discontinuation of atenolol is recommended.<xref ref-type="bibr" rid="article-655.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Caution is advised when using rivastigmine concurrently with&#x000a0;&#x003b2;-blockers such as atenolol, especially in patients with sick sinus syndrome or cardiovascular comorbidities due to the risk of syncope and bradycardia.<xref ref-type="bibr" rid="article-655.r32">[32]</xref><xref ref-type="bibr" rid="article-655.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administering atenolol concurrently with amiodarone, digoxin, or verapamil may cause heart block, bradycardia, and left ventricular dysfunction.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Antipsychotics and &#x003b2;-blockers have the&#x000a0;potential for&#x000a0;interactions. A case report documenting bradycardia induced by the combination of risperidone and atenolol has been published.<xref ref-type="bibr" rid="article-655.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As amifostine can cause a rapid drop in blood pressure, it is advisable to avoid concurrently using blood pressure&#x02013;lowering agents, including atenolol, with amifostine.<xref ref-type="bibr" rid="article-655.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As the American Academy of Family Physicians (AAFP) guidelines recommend, &#x003b2;-blockers, such as atenolol, should be tapered and discontinued several days before discontinuing clonidine to reduce the risk of rebound hypertension.<xref ref-type="bibr" rid="article-655.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-655.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to atenolol include sinus bradycardia, second or third-degree heart block, cardiogenic shock, and decompensated heart&#x000a0;failure. Atenolol is contraindicated in patients with a history of hypersensitivity to atenolol or its excipients. Cases of anaphylaxis&#x000a0;have been reported with &#x003b2;-blockers.<xref ref-type="bibr" rid="article-655.r37">[37]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Atenolol should not be discontinued abruptly, as doing so may worsen angina, acute myocardial infarction, or ventricular arrhythmias. Therefore, tapering the dose gradually is recommended.<xref ref-type="bibr" rid="article-655.r38">[38]</xref>&#x000a0;If worsening angina or the development of acute coronary insufficiency occurs, temporarily restarting atenolol is advised.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Atenolol use is contraindicated in patients with severe peripheral arterial disease, metabolic acidosis, and pheochromocytoma.&#x000a0;The drug should also be avoided in individuals with a history of asthma, bronchospasm, or other obstructive airway diseases unless no alternative is available. If no alternative is available, atenolol may be administered alongside a bronchodilator.<xref ref-type="bibr" rid="article-655.r39">[39]</xref><xref ref-type="bibr" rid="article-655.r40">[40]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Caution is advised when prescribing atenolol to diabetic or thyroid patients due to the potential for masking the symptoms of hypoglycemia and thyrotoxicosis. Rapid withdrawal may also precipitate a thyroid storm, emphasizing the need for careful management of the conditions in these populations.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prescribers should exercise caution during pregnancy, as atenolol has been demonstrated to cross the placental barrier and is associated with&#x000a0;intrauterine growth restriction.<xref ref-type="bibr" rid="article-655.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The American Academy of Pediatrics (AAP) advises against the use of atenolol during breastfeeding due to the potential risk of neonatal hypoglycemia and bradycardia.<xref ref-type="bibr" rid="article-655.r41">[41]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-655.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The elimination half-life of atenolol is approximately 6 to 7 hours. The &#x003b2;-blocking effects manifest within&#x000a0;1 hour of ingesting a single oral dose and persist for 24 hours. When administered IV, the effects of atenolol are noticeable within 5 minutes, but they diminish after 12 hours. Unlike other &#x003b2;-1-blocking agents, atenolol undergoes minimal hepatic metabolism and is primarily excreted through the kidneys. Consequently, no hepatic dosage adjustment is necessary. However, evaluating renal function before initiating treatment and regular monitoring throughout the course is important.&#x000a0;As impaired glomerular function leads to a substantial accumulation of the drug in the body, patients with a creatinine clearance below 35 mL/min should receive significantly lower doses.<xref ref-type="bibr" rid="article-655.r15">[15]</xref></p>
        <p>Periodic monitoring of blood pressure and heart rate is recommended.<xref ref-type="bibr" rid="article-655.r14">[14]</xref> The atherosclerotic cardiovascular disease (ASCVD) risk for primary prevention should be calculated, and if the risk exceeds 10%, the ACC/AHA guidelines recommend a target blood pressure of &#x0003c;130/80 mm Hg.<xref ref-type="bibr" rid="article-655.r42">[42]</xref>&#x000a0;Furthermore,&#x000a0;clinicians should ensure that patients with a history of obstructive airway disease undergo regular pulmonary function tests and that patients with diabetes&#x000a0;are monitored for their blood glucose levels.<xref ref-type="bibr" rid="article-655.r43">[43]</xref></p>
      </sec>
      <sec id="article-655.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Symptoms of atenolol toxicity may include bradycardia, lethargy, hypotension, respiratory drive disorders, hypothermia, hypoglycemia, and seizures.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>The treatment for &#x003b2;-blocker toxicity is primarily supportive. If administered orally, any unabsorbed drug can be removed by gastric lavage or activated charcoal (within 1 to 2 hours). Hemodialysis is effective in eliminating atenolol from the general systemic circulation.<xref ref-type="bibr" rid="article-655.r44">[44]</xref>&#x000a0;Inotropes and chronotropes, such as&#x000a0;IV epinephrine and atropine, are recommended for treating severe bradycardia. Usually,&#x000a0;atropine is administered as a 0.5-mg&#x000a0;IV or intraosseous bolus and may be repeated every 3 to 5 minutes, up to a total dose of 3 mg. A transvenous cardiac pacemaker may also be utilized in refractory cases or for treating second- or third-degree heart block.</p>
        <p>A titrated glucagon bolus at a dose of 50 mcg/kg can improve myocardial contractility and atrioventricular conduction and increase heart rate in patients. Continuous blood pressure monitoring is imperative, and vasopressors such as norepinephrine (levarterenol) may be considered in hypotension. A &#x003b2;-2 agonist such as aminophylline or isoproterenol may alleviate symptoms for patients with bronchospasm.&#x000a0;In cases refractory to the standard treatment, high-dose insulin euglycemic therapy, initiated with a 1 unit/kg bolus followed by a 1 unit/kg/h drip, may be considered to manage overdose under the guidance of a toxicologist.<xref ref-type="bibr" rid="article-655.r45">[45]</xref>&#x000a0;</p>
        <p>Lignocaine can be used in the management of arrhythmias resulting from &#x003b2;-blocker toxicity.&#x000a0;Veno-arterial extracorporeal membrane oxygenation is also associated with&#x000a0;reduced mortality.<xref ref-type="bibr" rid="article-655.r46">[46]</xref> For asymptomatic &#x003b2;-1-blocker overdoses, monitoring the patient for at least 6 hours is recommended.<xref ref-type="bibr" rid="article-655.r47">[47]</xref></p>
      </sec>
      <sec id="article-655.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Beta-1-selective adrenergic antagonists, such as atenolol, have widespread use for the treatment of hypertension, angina, and myocardial infarction. Despite not being the first-line treatment in hypertensive patients without compelling indications, AHA demonstrates that &#x003b2;-blockers are commonly utilized as initial pharmacological therapy for hypertension in clinical practice.<xref ref-type="bibr" rid="article-655.r48">[48]</xref></p>
        <p>An interprofessional healthcare team, including clinicians (MDs, DOs, NPs, and PAs), nurses, and pharmacists, must comprehensively understand the indications, adverse drug reactions, and contraindications associated with atenolol. Nurses responsible for administering atenolol should actively monitor for adverse drug reactions and be aware that the drug's effects may mask the symptoms of hypoglycemia and thyrotoxicosis. Nursing staff can provide counseling on medicine administration, verify patient adherence, assess the regimen's effectiveness during follow-up visits, and communicate any concerns to the clinician.&#x000a0;Pharmacists should verify dosing based on individual patient parameters and check for potential interactions that could alter therapeutic results.</p>
        <p>All members of the interprofessional team must maintain accurate and updated records. If any issues are identified, immediate communication with the prescriber is essential to convey concerns and facilitate potential modifications to the therapy. The interprofessional healthcare team overseeing the patient's care should consistently monitor renal function, heart rate, and blood pressure. This collaborative approach&#x000a0;contributes to therapeutic success and ensures optimal outcomes for patients using atenolol.</p>
        <p>In a pragmatic randomized controlled trial, a team-based care intervention involving collaboration among clinicians, pharmacists, and nurses was implemented for patients with uncontrolled hypertension. The findings demonstrated that this interprofessional approach had the potential to decrease long-term systolic blood pressure in individuals with uncontrolled hypertension receiving antihypertensive therapy, including &#x003b2;-blockers.<xref ref-type="bibr" rid="article-655.r49">[49]</xref></p>
      </sec>
      <sec id="article-655.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=655&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=655">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/655/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=655">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-655.s11">
        <title>References</title>
        <ref id="article-655.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadworth</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Murdoch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.</article-title>
            <source>Drugs</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>468</fpage>
            <page-range>468-510</page-range>
            <pub-id pub-id-type="pmid">1720383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ailani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>MS</given-names>
              </name>
              <collab>Board of Directors of the American Headache Society</collab>
            </person-group>
            <article-title>The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.</article-title>
            <source>Headache</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>61</volume>
            <issue>7</issue>
            <fpage>1021</fpage>
            <page-range>1021-1039</page-range>
            <pub-id pub-id-type="pmid">34160823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial.</article-title>
            <source>JAMA Otolaryngol Head Neck Surg</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>147</volume>
            <issue>7</issue>
            <fpage>599</fpage>
            <page-range>599-607</page-range>
            <pub-id pub-id-type="pmid">33856430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Argoff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>E</given-names>
              </name>
              <collab>Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</collab>
            </person-group>
            <article-title>Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Apr</month>
            <day>24</day>
            <volume>78</volume>
            <issue>17</issue>
            <fpage>1337</fpage>
            <page-range>1337-45</page-range>
            <pub-id pub-id-type="pmid">22529202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santomasso</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Lacchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anadkat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Brassil</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Caterino</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ernstoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Fecher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jaiyesimi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mammen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Naing</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Reichner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Seigel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Spira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suarez-Almazor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swami</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vikas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Funchain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bollin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2021</year>
            <month>Dec</month>
            <day>20</day>
            <volume>39</volume>
            <issue>36</issue>
            <fpage>4073</fpage>
            <page-range>4073-4126</page-range>
            <pub-id pub-id-type="pmid">34724392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Helfand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thakurta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <source>Drug Class Review: Beta Adrenergic Blockers: Final Report Update 4 [Internet]</source>
            <publisher-name>Oregon Health &#x00026; Science University</publisher-name>
            <publisher-loc>Portland (OR)</publisher-loc>
            <year>2009</year>
            <month>07</month>
            <pub-id pub-id-type="pmid">21089245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Speight</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Avery</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.</article-title>
            <source>Drugs</source>
            <year>1979</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>425</fpage>
            <page-range>425-60</page-range>
            <pub-id pub-id-type="pmid">38096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakaya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hattori</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abiko</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Atenolol, its cardioselective property for adrenergic beta-receptor blocking action and effect on the cardiac function (author's transl)].</article-title>
            <source>Nihon Yakurigaku Zasshi</source>
            <year>1980</year>
            <month>Oct</month>
            <volume>76</volume>
            <issue>7</issue>
            <fpage>621</fpage>
            <page-range>621-32</page-range>
            <pub-id pub-id-type="pmid">6111522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Indik</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Olshansky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <collab>Evidence Review Committee Chair&#x02021;</collab>
            </person-group>
            <article-title>2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Apr</month>
            <day>05</day>
            <volume>133</volume>
            <issue>14</issue>
            <fpage>e506</fpage>
            <page-range>e506-74</page-range>
            <pub-id pub-id-type="pmid">26399663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sl&#x000e4;ttengren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Lange</surname>
                <given-names>ECM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hammarlund-Udenaes</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Revisiting atenolol as a low passive permeability marker.</article-title>
            <source>Fluids Barriers CNS</source>
            <year>2017</year>
            <month>Oct</month>
            <day>31</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <pub-id pub-id-type="pmid">29089037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zisaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miskovic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hatzimanikatis</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.</article-title>
            <source>Curr Pharm Des</source>
            <year>2015</year>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>806</fpage>
            <page-range>806-22</page-range>
            <pub-id pub-id-type="pmid">25341854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ripley</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;-blockers: a review of their pharmacological and physiological diversity in hypertension.</article-title>
            <source>Ann Pharmacother</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>723</fpage>
            <page-range>723-33</page-range>
            <pub-id pub-id-type="pmid">24687542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shirasaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1872</fpage>
            <page-range>1872-81</page-range>
            <pub-id pub-id-type="pmid">26374172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1269</fpage>
            <page-range>1269-1324</page-range>
            <pub-id pub-id-type="pmid">29133354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mutschler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of atenolol in relation to renal function.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1981</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-71</page-range>
            <pub-id pub-id-type="pmid">7461026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fihn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gardin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blankenship</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dallas</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Foody</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Hinderliter</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kligfield</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Munger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Prager</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sabik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Sikkema</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force</collab>
            </person-group>
            <article-title>2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Dec</month>
            <day>18</day>
            <volume>126</volume>
            <issue>25</issue>
            <fpage>e354</fpage>
            <page-range>e354-471</page-range>
            <pub-id pub-id-type="pmid">23166211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Creager</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>e362</fpage>
            <page-range>e362-425</page-range>
            <pub-id pub-id-type="pmid">23247304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Preventive Migraine Treatment.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4 Headache</issue>
            <fpage>973</fpage>
            <page-range>973-89</page-range>
            <pub-id pub-id-type="pmid">26252585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Laurberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Rivkees</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stan</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</article-title>
            <source>Thyroid</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>1343</fpage>
            <page-range>1343-1421</page-range>
            <pub-id pub-id-type="pmid">27521067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tieu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Velenosi</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Kucey</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Urquhart</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title><italic>&#x003b2;</italic>-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>06</day>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>604</fpage>
            <page-range>604-611</page-range>
            <pub-id pub-id-type="pmid">29519953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regitz-Zagrosek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blomstr&#x000f6;m-Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>C&#x000ed;fkov&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kintscher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Seeland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Simoncini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>07</day>
            <volume>39</volume>
            <issue>34</issue>
            <fpage>3165</fpage>
            <page-range>3165-3241</page-range>
            <pub-id pub-id-type="pmid">30165544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <chapter-title>Atenolol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>8</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">30000201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krowchuk</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Frieden</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Darrow</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Blei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Annam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Frommelt</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hodak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pate</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sandrock</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>MA</given-names>
              </name>
              <collab>SUBCOMMITTEE ON THE MANAGEMENT OF INFANTILE HEMANGIOMAS</collab>
            </person-group>
            <article-title>Clinical Practice Guideline for the Management of Infantile Hemangiomas.</article-title>
            <source>Pediatrics</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>143</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30584062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidouris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Worth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Date</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jasser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hird</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tetlow</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Notes for the general paediatrician: managing thyrotoxicosis in children and young people.</article-title>
            <source>BMJ Paediatr Open</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36645751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacro</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Dietz</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Sleeper</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Yetman</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Colan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Selamet Tierney</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Atz</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gelb</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Grossfeld</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loeys</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Markham</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Paridon</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Pemberton</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Pierpont</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pyeritz</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Radojewski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sharkey</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Stylianou</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Mahony</surname>
                <given-names>L</given-names>
              </name>
              <collab>Pediatric Heart Network Investigators</collab>
            </person-group>
            <article-title>Atenolol versus losartan in children and young adults with Marfan's syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Nov</month>
            <day>27</day>
            <volume>371</volume>
            <issue>22</issue>
            <fpage>2061</fpage>
            <page-range>2061-71</page-range>
            <pub-id pub-id-type="pmid">25405392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Fleg</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pepine</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Artinian</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ferdinand</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Forciea</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Frishman</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Jaigobin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reisin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Schocken</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wesley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>ACCF Task Force</collab>
            </person-group>
            <article-title>ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>May</month>
            <day>31</day>
            <volume>123</volume>
            <issue>21</issue>
            <fpage>2434</fpage>
            <page-range>2434-506</page-range>
            <pub-id pub-id-type="pmid">21518977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <chapter-title>Beta Adrenergic Blocking Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>6</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31643457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <chapter-title>Atenolol</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">31643700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>880201</fpage>
            <pub-id pub-id-type="pmid">35757712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailuni Neto</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Siqueira</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Boros</surname>
                <given-names>GAB</given-names>
              </name>
              <name>
                <surname>Akamine</surname>
                <given-names>MAV</given-names>
              </name>
              <name>
                <surname>Cordeiro de Paula</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Rodrigues de Assis</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Scudeler</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>BRASH Syndrome: A Case Report.</article-title>
            <source>Am J Case Rep</source>
            <year>2022</year>
            <month>Jan</month>
            <day>21</day>
            <volume>23</volume>
            <fpage>e934600</fpage>
            <pub-id pub-id-type="pmid">35058422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoury</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rajamanickam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grossberg</surname>
                <given-names>GT</given-names>
              </name>
            </person-group>
            <article-title>An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-178</page-range>
            <pub-id pub-id-type="pmid">29492246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulison</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>L&#x000e9;os</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature.</article-title>
            <source>Cardiovasc Toxicol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-10</page-range>
            <pub-id pub-id-type="pmid">20865460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siwek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woro&#x00144;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gorostowicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wordliczek</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders.</article-title>
            <source>Pharmacol Rep</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>350</fpage>
            <page-range>350-359</page-range>
            <pub-id pub-id-type="pmid">32124390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varghese</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Schmale</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Mickelsen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Newlands</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Benoit</surname>
                <given-names>DSW</given-names>
              </name>
              <name>
                <surname>Korshunov</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Ovitt</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection.</article-title>
            <source>J Dent Res</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>97</volume>
            <issue>11</issue>
            <fpage>1252</fpage>
            <page-range>1252-1259</page-range>
            <pub-id pub-id-type="pmid">29634396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carpenter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Clinically Relevant Drug-Drug Interactions in Primary Care.</article-title>
            <source>Am Fam Physician</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>99</volume>
            <issue>9</issue>
            <fpage>558</fpage>
            <page-range>558-564</page-range>
            <pub-id pub-id-type="pmid">31038898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Greger</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kahoud</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lohse</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Patients Taking &#x003b2;-Blockers Do Not Require Increased Doses of Epinephrine for Anaphylaxis.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>1553</fpage>
            <page-range>1553-1558.e1</page-range>
            <pub-id pub-id-type="pmid">29449164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koracevic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Micic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stojanovic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon.</article-title>
            <source>Curr Vasc Pharmacol</source>
            <year>2021</year>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>624</fpage>
            <page-range>624-633</page-range>
            <pub-id pub-id-type="pmid">33653252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lammers</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Folgering</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>van Herwaarden</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1986</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>595</fpage>
            <page-range>595-602</page-range>
            <pub-id pub-id-type="pmid">2878680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruffin</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Latimer</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Crockett</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Alpers</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Assessment of beta-adrenoceptor antagonists in asthmatic patients.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1982</year>
            <volume>13</volume>
            <issue>Suppl 2</issue>
            <fpage>325S</fpage>
            <page-range>325S-335S</page-range>
            <pub-id pub-id-type="pmid">6125185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eyal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Brateng</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Woodrum</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Easterling</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Hebert</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>11</issue>
            <fpage>1301</fpage>
            <page-range>1301-9</page-range>
            <pub-id pub-id-type="pmid">20145263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnett</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buroker</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Himmelfarb</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Michos</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Miedema</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ziaeian</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular&#x000a0;Disease: A Report of the American College of Cardiology/American Heart Association Task&#x000a0;Force&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>10</day>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>e177</fpage>
            <page-range>e177-e232</page-range>
            <pub-id pub-id-type="pmid">30894318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <collab>UK Prospective Diabetes Study Group</collab>
            <article-title>Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.</article-title>
            <source>BMJ</source>
            <year>1998</year>
            <month>Sep</month>
            <day>12</day>
            <volume>317</volume>
            <issue>7160</issue>
            <fpage>713</fpage>
            <page-range>713-20</page-range>
            <pub-id pub-id-type="pmid">9732338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Druda</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>453</fpage>
            <page-range>453-61</page-range>
            <pub-id pub-id-type="pmid">26344579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stellpflug</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Engebretsen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Holger</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Intentional overdose with cardiac arrest treated with intravenous fat emulsion and high-dose insulin.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-9</page-range>
            <pub-id pub-id-type="pmid">20141425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rotella</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Koutsogiannis</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hung Leang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bourke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment for beta-blocker poisoning: a systematic review.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>943</fpage>
            <page-range>943-983</page-range>
            <pub-id pub-id-type="pmid">32310006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r47">
          <label>47</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tucker</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Theetha Kariyanna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Selective Beta-1 Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29763157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan You</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Suchard</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schuemie</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hripcsak</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Madigan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Woong Park</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive Comparative Effectiveness and Safety of First-Line &#x003b2;-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.</article-title>
            <source>Hypertension</source>
            <year>2021</year>
            <month>May</month>
            <day>05</day>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>1528</fpage>
            <page-range>1528-1538</page-range>
            <pub-id pub-id-type="pmid">33775125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-655.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santschi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wuerzner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pais</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chiolero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schaller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cloutier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paradis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Team-Based Care for Improving Hypertension Management: A Pragmatic Randomized Controlled Trial.</article-title>
            <source>Front Cardiovasc Med</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>760662</fpage>
            <pub-id pub-id-type="pmid">34760950</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
